Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.
Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez-Perez NN, Arriens C, Parikh SV, Caster DJ, Birardi V, Randhawa S, Lisk L, Huizinga RB, Teng YKO. Saxena A, et al. Arthritis Rheumatol. 2024 Jan;76(1):59-67. doi: 10.1002/art.42657. Epub 2023 Sep 15. Arthritis Rheumatol. 2024. PMID: 37466424
Lupus community panel proposals for optimising clinical trials: 2018.
Merrill JT, Manzi S, Aranow C, Askanase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP. Merrill JT, et al. Among authors: saxena a. Lupus Sci Med. 2018 Mar 23;5(1):e000258. doi: 10.1136/lupus-2018-000258. eCollection 2018. Lupus Sci Med. 2018. PMID: 29657738 Free PMC article. Review.
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O'Malley T, Dervieux T, Weinstein A. Ramsey-Goldman R, et al. Among authors: saxena a. Arthritis Rheumatol. 2020 Jan;72(1):78-88. doi: 10.1002/art.41093. Epub 2019 Nov 25. Arthritis Rheumatol. 2020. PMID: 31469249 Free PMC article.
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF 3rd, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. Atisha-Fregoso Y, et al. Among authors: saxena a. Arthritis Rheumatol. 2021 Jan;73(1):121-131. doi: 10.1002/art.41466. Epub 2020 Dec 1. Arthritis Rheumatol. 2021. PMID: 32755035 Free PMC article. Clinical Trial.
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Furie R, et al. Among authors: saxena a. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180. N Engl J Med. 2020. PMID: 32937045 Clinical Trial.
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B. Ginzler E, et al. Among authors: saxena a. Arthritis Rheumatol. 2022 Jan;74(1):112-123. doi: 10.1002/art.41900. Epub 2021 Dec 9. Arthritis Rheumatol. 2022. PMID: 34164944 Free PMC article. Clinical Trial.
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis.
Arriens C, Teng YKO, Ginzler EM, Parikh SV, Askanase AD, Saxena A, Gibson K, Caster DJ, Atsumi T, Lisk L, Randhawa S, Gluck R, Solomons N, Huizinga RB. Arriens C, et al. Among authors: saxena a. Arthritis Care Res (Hoboken). 2023 Jul;75(7):1399-1408. doi: 10.1002/acr.25007. Epub 2023 Feb 12. Arthritis Care Res (Hoboken). 2023. PMID: 36039949 Clinical Trial.
Cell-bound complement activation products associate with lupus severity in SLE.
Arriens C, Alexander RV, Narain S, Saxena A, Collins CE, Wallace DJ, Massarotti E, Conklin J, Kalunian KC, Putterman C, Ramsey-Goldman R, Buyon JP, Askanase A, Furie RA, James JA, Bello GA, Manzi S, Ahearn J, O'Malley T, Weinstein A, Dervieux T. Arriens C, et al. Among authors: saxena a. Lupus Sci Med. 2020 Apr;7(1):e000377. doi: 10.1136/lupus-2019-000377. Lupus Sci Med. 2020. PMID: 32371480 Free PMC article.
3,696 results